Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameHeartcare-B
Stock Code06609
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家創新型神經介入醫療器械公司,產品組合包括神經介入及心臟醫療器械,憑藉研發、生產及商業化能力,致力降低中國乃至全球的腦卒中死亡率並改善預後。
Listing Date2021-08-20
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)上海市自由貿易試驗區臨港新片區正博路356號38幢第1層、第3層
Business Address (Hong Kong)德輔道中161號香港貿易中心19樓1903-4室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitestrokemedical.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 171.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size50 shares
Entry ThresholdHK$ 8,550
Par ValueRMB 1.0 / shares
Offer Period2021-08-10 to 2021-08-13
Global Offering Shares6,601,850 shares
HK Public Offer Shares (Initial)660,200 shares (10.0%)
Public Offer Lots (Initial)13,204lots (Pool A6,602lots,Pool B6,602lots)
International Placing Shares (Initial)5,941,650 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO38,834,408 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share45.5%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,128,916,350

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 50 HK$ 8,550
2 lots 100 HK$ 17,100
3 lots 150 HK$ 25,650
4 lots 200 HK$ 34,200
5 lots 250 HK$ 42,750
6 lots 300 HK$ 51,300
7 lots 350 HK$ 59,850
8 lots 400 HK$ 68,400
9 lots 450 HK$ 76,950
10 lots 500 HK$ 85,500
12 lots 600 HK$ 102,600
14 lots 700 HK$ 119,700
16 lots 800 HK$ 136,800
18 lots 900 HK$ 153,900
20 lots 1,000 HK$ 171,000
30 lots 1,500 HK$ 256,500
40 lots 2,000 HK$ 342,000
50 lots 2,500 HK$ 427,500
60 lots 3,000 HK$ 513,000
70 lots 3,500 HK$ 598,500
80 lots 4,000 HK$ 684,000
90 lots 4,500 HK$ 769,500
100 lots 5,000 HK$ 855,000
120 lots 6,000 HK$ 1,026,000
140 lots 7,000 HK$ 1,197,000
160 lots 8,000 HK$ 1,368,000
180 lots 9,000 HK$ 1,539,000
200 lots 10,000 HK$ 1,710,000
300 lots 15,000 HK$ 2,565,000
400 lots 20,000 HK$ 3,420,000
500 lots 25,000 HK$ 4,275,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 30,000 HK$ 5,130,000
700 lots 35,000 HK$ 5,985,000
800 lots 40,000 HK$ 6,840,000
900 lots 45,000 HK$ 7,695,000
1,000 lots 50,000 HK$ 8,550,000
1,200 lots 60,000 HK$ 10,260,000
1,400 lots 70,000 HK$ 11,970,000
1,600 lots 80,000 HK$ 13,680,000
1,800 lots 90,000 HK$ 15,390,000
2,000 lots 100,000 HK$ 17,100,000
3,000 lots 150,000 HK$ 25,650,000
4,000 lots 200,000 HK$ 34,200,000
6,602 lots 330,100 HK$ 56,447,100

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.52B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +516%

Valuation & Financials

Market Cap (at Offer Price)HK$ 6,640,683,768
H-Share Market Cap (at Offer Price)HK$ 5,397,752,484
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣216.2百萬元
Period-End Cash Balance人民幣632.4百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Revenue 014,562
Cost of sales 0-7,475
Gross profit 07,087
Other income and gains, net 3,1086,000
Selling and distribution expenses -1,039-14,278
Administrative expenses -26,395-141,869
Net finance costs -62-1,604
Profit before tax -75,498-216,183
Income tax expense 00
Profit for the year -75,498-216,183
Profit attributable to owners -75,498-213,664
Balance Sheet
Item 20192020
Cash and cash equivalents 25,548632,418
Trade and bills receivables 00
Inventories 2478,638
Total current assets 64,269661,782
Total assets 91,283773,631
Total current liabilities 4,31336,612
Total liabilities 10,21082,596
Total equity 81,073691,035
Equity attributable to owners 81,073681,368
Cash Flow Statement
Item 201920202021-03
Net cash from operating activities -32,291-74,814
Net cash from investing activities -45,293-4,534
Net cash from financing activities 94,499686,218
Net increase in cash 16,915606,870
Depreciation of PP&E 1,4804,9521,406
Depreciation of right-of-use assets 8623,433864
Purchase of PP&E -20,815-15,605-11,287
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 129.0
First Day OpenHK$ 141.2
First Day Change-24.56%
First Day Volume2053800.0
First Day Turnover281742000.0
Use of Proceeds
1、約45.3%或約459.7百萬港元預期將分配至我們的核心產品; 2、約39.9%所或約404.9百萬港元預期將分配至我們管線內的其他在研產品; 3、約4.8%或約48.7百萬港元用于為透過內部研究提升研發能力及持續擴充產品組合提供資金; 4、約10.0%或約101.5百萬港元預期將用作營運資金及一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 富途证券国际(香港)有限公司 CE AZT137
Joint Lead Managers (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 富途证券国际(香港)有限公司 CE AZT137

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 3W Funds 23,324,400 HKD — 2.07% — 6 months 2022-02-20
2 Aspex Master Fund 77,745,150 HKD — 6.89% — 6 months 2022-02-20
3 Boyu Capital Opportunities Master Fund 77,745,150 HKD — 6.89% — 6 months 2022-02-20
4 Goldstream Healthcare Focus Fund SP 23,324,400 HKD — 2.07% — 6 months 2022-02-20
5 Lake Bleu Prime Healthcare Master Fund Limited 77,745,150 HKD — 6.89% — 6 months 2022-02-20
6 LYFE CAPITAL FUND III (DRAGON), L.P. 38,868,300 HKD — 3.44% — 6 months 2022-02-20
7 Octagon Investments Master Fund LP 77,745,150 HKD — 6.89% — 6 months 2022-02-20
8 Sage Partners Master Fund 38,868,300 HKD — 3.44% — 6 months 2022-02-20
9 Superstring Capital Master Fund LP 38,868,300 HKD — 3.44% — 6 months 2022-02-20
10 The Valliance Fund 38,868,300 HKD — 3.44% — 6 months 2022-02-20

Directors & Management

PositionChinese nameEnglish Name
Chairman王國輝—
Company Secretary張涵—
No director data available.

Major Shareholders

Major Shareholders & Holdings王國輝先生、心瑋投資、楷遠投資、瑋鈺上海及瑋鋆上海被視為一組單一最大股東,合共持有本公司已發行股本約29.20%;LYFE Capital Management Limited持有約13.06%。
About this page

This page shows Heartcare-B (06609) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect